Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Lansen Buys 20% of Zhejiang Starry Pharma

publication date: Nov 16, 2010
Lansen Pharmaceutical will purchase 20% of Zhejiang Starry Pharmaceutical Co. from an individual for 160 million RMB ($24 million). Starry, a bulk pharmaceutical and intermediate company, is the largest manufacturer of the contrast agent iohexol in the PRC. For the year ended 31 December 2009, Starry’s profit after taxation was $9 million, and it listed net asset value of $30 million. More details....

Stock Symbol: (HKEX: 0503)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital